|
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
02-Jul-2021 / 10:36 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Aubagne, July 2, 2021
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:
- 2,374 shares
- € 9,177,482.91
- Number of executions on buy side on semester: 659
- Number of executions on sell side on semester: 538
- Traded volume on buy side on semester: 24,109 shares for € 8,777,527.71
- Traded volume on sell side on semester: 21,735 shares for € 7,961,330.63
As a reminder, the following resources appeared on the liquidity account when the activity started:
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.
Contact
Ben Orzelek
Head of Investor Relations
+49 (0)551.308.1668
Ben.orzelek@sartorius.com
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com
Transactions executed by Gilbert Dupont (liquidity provider until March 9, 2021):
|
|
Buy side
|
Sell side
|
|
|
Number of executions
|
Number of shares
|
Traded volume in EUR
|
Number of executions
|
Number of shares
|
Traded volume in EUR
|
|
TOTAL
|
1
|
0
|
0,00
|
10
|
73
|
26,218.80
|
|
04/01/2021
|
0
|
0
|
0
|
1
|
10
|
3,028
|
|
05/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
06/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
07/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
08/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
11/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
12/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
13/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
14/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
15/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
18/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
19/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
20/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
21/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
22/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
25/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
26/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
27/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
28/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
29/01/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
01/02/2021
|
0
|
0
|
0
|
2
|
11
|
3,854.4
|
|
02/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
03/02/2021
|
0
|
0
|
0
|
1
|
20
|
7,600
|
|
04/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
05/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
08/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
09/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
10/02/2021
|
0
|
0
|
0
|
2
|
15
|
6,000
|
|
11/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
12/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
15/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
16/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
17/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
18/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
19/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
22/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
23/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
24/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
25/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
26/02/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
01/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
02/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
03/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
04/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
05/03/2021
|
1
|
0
|
0
|
1
|
0
|
0
|
|
08/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
09/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
|
10/03/2021
|
0
|
0
|
0
|
3
|
17
|
5,736.4
|
|
11/03/2021
|
0
|
0
|
0
|
0
|
0
|
0
|
Transactions executed by Kepler Cheuvreux (liquidity provider as of on May 4, 2021):
|
|
Buy side
|
Sell side
|
|
|
Number of executions
|
Number of shares
|
Traded volume in EUR
|
Number of executions
|
Number of shares
|
Traded volume in EUR
|
|
TOTAL
|
659
|
24,109
|
8,777,527.71
|
538
|
21,735
|
7,961,330.63
|
|
07/05/2021
|
26
|
900
|
327,780.00
|
5
|
450
|
168,525.00
|
|
10/05/2021
|
109
|
5,109
|
1,873,112.67
|
-
|
-
|
-
|
|
11/05/2021
|
66
|
1,800
|
639,198.00
|
1
|
100
|
35,900.00
|
|
12/05/2021
|
10
|
500
|
176,700.00
|
8
|
503
|
179,374.83
|
|
13/05/2021
|
10
|
500
|
177,000.00
|
27
|
1,097
|
390,970.80
|
|
14/05/2021
|
4
|
400
|
143,400.00
|
14
|
700
|
252,098.00
|
|
17/05/2021
|
13
|
700
|
250,803.00
|
14
|
1,500
|
542,715.00
|
|
18/05/2021
|
19
|
700
|
247,877.00
|
19
|
200
|
71,400.00
|
|
19/05/2021
|
35
|
900
|
314,001.00
|
-
|
-
|
-
|
|
20/05/2021
|
-
|
-
|
-
|
26
|
1,000
|
353,560.00
|
|
21/05/2021
|
2
|
200
|
70,520.00
|
6
|
100
|
35,900.00
|
|
24/05/2021
|
3
|
100
|
35,200.00
|
-
|
-
|
-
|
|
25/05/2021
|
2
|
100
|
35,400.00
|
10
|
300
|
107,100.00
|
|
26/05/2021
|
11
|
400
|
144,200.00
|
82
|
3,600
|
1,307,088.00
|
|
27/05/2021
|
22
|
1,100
|
390,126.00
|
-
|
-
|
-
|
|
28/05/2021
|
14
|
400
|
140,520.00
|
-
|
-
|
-
|
|
31/05/2021
|
3
|
100
|
35,500.00
|
3
|
100
|
36,100.00
|
|
01/06/2021
|
5
|
300
|
105,900.00
|
6
|
200
|
71,700.00
|
|
02/06/2021
|
48
|
2,100
|
727,188.00
|
13
|
200
|
70,900.00
|
|
03/06/2021
|
10
|
500
|
170,000.00
|
1
|
5
|
1,735.00
|
|
04/06/2021
|
-
|
-
|
-
|
16
|
700
|
240,121.00
|
|
07/06/2021
|
7
|
300
|
102,600.00
|
7
|
280
|
96,860.40
|
|
08/06/2021
|
5
|
300
|
106,200.00
|
38
|
2,200
|
781,132.00
|
|
09/06/2021
|
5
|
200
|
70,300.00
|
26
|
1,100
|
396,033.00
|
|
10/06/2021
|
10
|
400
|
145,400.00
|
49
|
1,128
|
416,062.80
|
|
11/06/2021
|
7
|
200
|
73,700.00
|
12
|
572
|
213,710.64
|
|
14/06/2021
|
-
|
-
|
-
|
26
|
1,000
|
379,850.00
|
|
15/06/2021
|
3
|
200
|
77,300.00
|
13
|
600
|
232,698.00
|
|
16/06/2021
|
6
|
200
|
76,900.00
|
7
|
300
|
116,100.00
|
|
17/06/2021
|
95
|
2,200
|
829,004.00
|
3
|
100
|
37,700.00
|
|
18/06/2021
|
9
|
200
|
75,500.00
|
25
|
900
|
343,197.00
|
|
21/06/2021
|
34
|
800
|
300,784.00
|
2
|
100
|
37,600.00
|
|
22/06/2021
|
3
|
100
|
37,490.00
|
9
|
500
|
189,200.00
|
|
23/06/2021
|
2
|
100
|
37,800.00
|
4
|
118
|
45,039.42
|
|
24/06/2021
|
1
|
100
|
37,800.00
|
36
|
1,282
|
493,659.74
|
|
25/06/2021
|
2
|
100
|
38,600.00
|
9
|
200
|
78,500.00
|
|
28/06/2021
|
-
|
-
|
-
|
21
|
600
|
238,800.00
|
|
29/06/2021
|
1
|
1
|
402.00
|
-
|
-
|
-
|
|
30/06/2021
|
57
|
1,899
|
763,322.04
|
-
|
-
|
-
|
Regulatory filing PDF file
File: Half-year liquidity contract statement for Sartorius Stedim Biotech
|
